These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
121 related items for PubMed ID: 37832873
1. Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease. Chen J, Farraj RA, Limonta D, Tabatabaei Dakhili SA, Kerek EM, Bhattacharya A, Reformat FM, Mabrouk OM, Brigant B, Pfeifer TA, McDermott MT, Ussher JR, Hobman TC, Glover JNM, Hubbard BP. J Biol Chem; 2023 Nov; 299(11):105341. PubMed ID: 37832873 [Abstract] [Full Text] [Related]
2. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition. Savale RU, Bhowmick S, Osman SM, Alasmary FA, Almutairi TM, Abdullah DS, Patil PC, Islam MA. Arch Biochem Biophys; 2021 Mar 30; 700():108771. PubMed ID: 33485847 [Abstract] [Full Text] [Related]
3. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp15 endoribonuclease. Canal B, Fujisawa R, McClure AW, Deegan TD, Wu M, Ulferts R, Weissmann F, Drury LS, Bertolin AP, Zeng J, Beale R, Howell M, Labib K, Diffley JFX. Biochem J; 2021 Jul 16; 478(13):2465-2479. PubMed ID: 34198324 [Abstract] [Full Text] [Related]
4. The coronavirus nsp15 endoribonuclease: A puzzling protein and pertinent antiviral drug target. Van Loy B, Stevaert A, Naesens L. Antiviral Res; 2024 Aug 16; 228():105921. PubMed ID: 38825019 [Abstract] [Full Text] [Related]
5. Identification of phytochemicals as potential therapeutic agents that binds to Nsp15 protein target of coronavirus (SARS-CoV-2) that are capable of inhibiting virus replication. Kumar S, Kashyap P, Chowdhury S, Kumar S, Panwar A, Kumar A. Phytomedicine; 2021 May 16; 85():153317. PubMed ID: 32943302 [Abstract] [Full Text] [Related]
11. Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15. Shalayel MH, Al-Mazaideh GM, Aladaileh SH, Al-Swailmi FK, Al-Thiabat MG. Pak J Pharm Sci; 2020 Sep 16; 33(5):2179-2186. PubMed ID: 33824127 [Abstract] [Full Text] [Related]
14. Inhibition of anti-viral stress granule formation by coronavirus endoribonuclease nsp15 ensures efficient virus replication. Gao B, Gong X, Fang S, Weng W, Wang H, Chu H, Sun Y, Meng C, Tan L, Song C, Qiu X, Liu W, Forlenza M, Ding C, Liao Y. PLoS Pathog; 2021 Feb 16; 17(2):e1008690. PubMed ID: 33635931 [Abstract] [Full Text] [Related]
17. Biochemical Characterization of Emerging SARS-CoV-2 Nsp15 Endoribonuclease Variants. Wilson IM, Frazier MN, Li JL, Randall TA, Stanley RE. J Mol Biol; 2022 Oct 30; 434(20):167796. PubMed ID: 35995266 [Abstract] [Full Text] [Related]
18. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp12/7/8 RNA-dependent RNA polymerase. Bertolin AP, Weissmann F, Zeng J, Posse V, Milligan JC, Canal B, Ulferts R, Wu M, Drury LS, Howell M, Beale R, Diffley JFX. Biochem J; 2021 Jul 16; 478(13):2425-2443. PubMed ID: 34198323 [Abstract] [Full Text] [Related]
19. SARS-CoV-2 nsp15 preferentially degrades AU-rich dsRNA via its dsRNA nickase activity. Wang X, Zhu B. Nucleic Acids Res; 2024 May 22; 52(9):5257-5272. PubMed ID: 38634805 [Abstract] [Full Text] [Related]
20. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment. Sixto-López Y, Martínez-Archundia M. J Comput Chem; 2021 May 15; 42(13):897-907. PubMed ID: 33713492 [Abstract] [Full Text] [Related] Page: [Next] [New Search]